Mucosis is a clinical-stage Dutch biotechnology company with a proprietary platform technology, Mimopath, on which it develops novel vaccines using various routes of administration including those that provide additional protection in the mucosa, the site where over 90% of pathogens enter the human body. Mucosis's lead product is SynGEM, a stabilized prefusion F protein recombinant vaccine to prevent RSV infection in various target groups. In addition, the company has developed PneuGEM, a vaccine to prevent diseases caused by pneumococcal bacteria and FluGEM, a vaccine to prevent influenza which served as a successful Mimopath platform proof of concept through human clinical testing.
Missing: Mucosis's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Mucosis's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Mucosis
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Mucosis is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Mucosis has filed 1 patent.
Clusters of differentiation, Immunology, Proteins, Immune system, Vaccines
Clusters of differentiation, Immunology, Proteins, Immune system, Vaccines
Latest Mucosis News
Aug 29, 2017
Home » Topics » Bioscience » Latest News » Mucosis BV Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23082017] Prices from USD $250 Summary Mucosis BV Mucosis is a biotechnology company that discovers and develops mucosal vaccines for prevention and treatment of infectious diseases . The company offers products such as intranasal vaccine to prevent respiratory syncytial virus infection. It provides products to protective against live parasites, viruses and bacteria. Mucosis' vaccines are based on the Mimopath technology. The company conducts research on development of vaccines that prevent diseases caused by respiratory tract pathogens. It partners with academic institutions and biotechnology companies. Mucosis is headquartered in Groningen, the Netherlands. Mucosis BV Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Mucosis Frequently Asked Questions (FAQ)
When was Mucosis founded?
Mucosis was founded in 2006.
Where is Mucosis's headquarters?
Mucosis's headquarters is located at L. J. Zielstraweg 1, Groningen.
What is Mucosis's latest funding round?
Mucosis's latest funding round is Distressed & Special Situation.
How much did Mucosis raise?
Mucosis raised a total of $24.23M.
Who are the investors of Mucosis?
Investors of Mucosis include Virtuvax, BioGeneration Ventures, MedSciences Capital Management, NOM, BCHT and 6 more.
Who are Mucosis's competitors?
Competitors of Mucosis include Zosano Pharma, ISA Pharmaceuticals, Scancell, Immune Design, Immune Targeting Systems and 11 more.
Compare Mucosis to Competitors
ISA Pharmaceuticals (Immune System Activation) is dedicated to fighting cancer and infectious diseases by providing ways to activate the patients immune system. Building on the work by internationally renowned tumor-immunology researcher Professor Kees Melief at the Leiden University Medical Center, the Netherlands, ISA Pharmaceuticals focuses on the development of synthetic peptide vaccines that boost the bodys immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. Thanks to a recent by the Melief-group, clinical studies (phase I/II) are showing highly promising results. The is the use of long peptides in therapeutic vaccines. This synthetic long peptide concept (SLP)aims to enable the activation of both cytotoxic T-cells (killer cells) and T-helper cells, which leads to activity of the immune systems against a tumor.
adjuvant system relying on the use of anti-CD40 antibodies mode of action may allow the system to be used in combination with other adjuvants and in situations where existing systems don't work Proof of concept achieved in pre-clinical studies Interested in partnering for vaccine development and to source anti CD40
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
The focus of Savine Therapeutics is to develop and commercialise vaccines for prevention and treatment of diseases using it's Scrambled Antigen Vaccine (SAVINE) technology. The technology was invented by researchers in the John Curtin School of Medical Research at the Australian National University. Per the company, it enables production of vaccines suitable for a broad range of serious worldwide infectious diseases and cancers. See www.savine.com
Developing genetically modified vaccines to protect against common seasonal influenza and emergent pandemic influenza. Formed to commercialize patented vaccine and virus technologies developed at the Mount Sinai School of Medicine, Vivaldi's program represents a approach to flu vaccine development and production and a major advance over flu vaccines available today.
ImmBio is a vaccine company developing vaccine systems. The portfolio addresses areas of high unmet need, where the risk and consequence of infection are severe.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.